Peng B et al., 2010-02-18: Randomized placebo-controlled trial of intradiscal methylene blue injection for chronic discogenic low back pain in 72 patients, reporting large 24-month pain reductions and 91.6% satisfaction. The usual citation for the claim, with unusually large effect sizes.
The patients in MB injection group showed a mean reduction in pain measured by NRS of 52.50, a mean reduction in Oswestry disability scores of 35.58, and satisfaction rates of 91.6%, compared with 0.70%, 1.68%, and 14.3%, respectively, in placebo treatment group (p<0.001, p<0.001, and p<0.001, respectively).
Peng B et al., 2010-02-18: Randomized placebo-controlled trial of intradiscal methylene blue injection for chronic discogenic low back pain in 72 patients, reporting large 24-month pain reductions and 91.6% satisfaction. The usual citation for the claim, with unusually large effect sizes. Study type: randomized, placebo-controlled trial. N=72 (36 MB, 36 placebo) from 136 screened. Country: China. Intradiscal injection; MB concentration, volume and dose not stated in abstract; single injection; 24-month follow-up. Funding/conflicts: not stated in record. Comparator: intradiscal placebo. Outcomes: NRS reduction 52.50 vs 0.70; ODI 35.58 vs 1.68; satisfaction 91.6% vs 14.3%. The paper says no adverse effects; later authors disputed the design (see Levine 2011, Kallewaard 2019). Study type: randomized trial.
